These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35887928)

  • 41. [Immunogenicity and safety of a booster vaccination with an inactivated severe acute respiratory syndrome coronavirus 2 vaccine in adults aged 18 to 59 years].
    Pan HX; Huang BY; Deng Y; Chu K; Hu JL; Zhu DD; Wu JL; Zhang L; Wang M; Huang WJ; Tan WJ
    Zhonghua Yi Xue Za Zhi; 2022 Jan; 102(4):279-285. PubMed ID: 35073677
    [No Abstract]   [Full Text] [Related]  

  • 42. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and immunogenicity of a third-dose homologous BBIBP-CorV boosting vaccination: interim results from a prospective open-label study.
    Ai J; Zhang Y; Zhang H; Zhang Q; Fu Z; Lin K; Song J; Zhao Y; Fan M; Wang H; Zhou Y; Chen X; Qiu C; Zhang W
    Emerg Microbes Infect; 2022 Dec; 11(1):639-647. PubMed ID: 35034582
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
    Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC
    Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Heterologous SARS-CoV-2 Booster Vaccinations - Preliminary Report.
    Atmar RL; Lyke KE; Deming ME; Jackson LA; Branche AR; El Sahly HM; Rostad CA; Martin JM; Johnston C; Rupp RE; Mulligan MJ; Brady RC; Frenck RW; Bäcker M; Kottkamp AC; Babu TM; Rajakumar K; Edupuganti S; Dobryzynski D; Posavad CM; Archer JI; Crandon S; Nayak SU; Szydlo D; Zemanek J; Dominguez Islas CP; Brown ER; Suthar MS; McElrath MJ; McDermott AB; O'Connell SE; Montefiori DC; Eaton A; Neuzil KM; Stephens DS; Roberts PC; Beigel JH;
    medRxiv; 2021 Oct; ():. PubMed ID: 34671773
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial.
    Li J; Hou L; Guo X; Jin P; Wu S; Zhu J; Pan H; Wang X; Song Z; Wan J; Cui L; Li J; Chen Y; Wang X; Jin L; Liu J; Shi F; Xu X; Zhu T; Chen W; Zhu F
    Nat Med; 2022 Feb; 28(2):401-409. PubMed ID: 35087233
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and immunogenicity of homologous versus heterologous booster dose with AZD1222, mRNA-1273, or MVC-COV1901 SARS-CoV-2 vaccines in adults: An observer-blinded, multi-center, phase 2 randomized trial.
    Estephan L; Lin YC; Lin YT; Chen YH; Pan SC; Hsieh SM; Torkehagen PF; Weng YJ; Cheng HY; Estrada JA; Waits A; Chen C; Lien CE
    Vaccine; 2023 May; 41(23):3497-3505. PubMed ID: 37080829
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant.
    Zang J; Yin Y; Xu S; Qiao W; Liu Q; Lavillette D; Zhang C; Wang H; Huang Z
    Front Immunol; 2022; 13():908478. PubMed ID: 35844601
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents.
    Vesikari T; Østergaard L; Beeslaar J; Absalon J; Eiden JJ; Jansen KU; Jones TR; Harris SL; Maansson R; Munson S; O'Neill RE; York LJ; Perez JL
    Vaccine; 2019 Mar; 37(12):1710-1719. PubMed ID: 30770221
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques.
    Deng W; Lv Q; Li F; Liu J; Song Z; Qi F; Wei Q; Yu P; Liu M; Zhou S; Zhang Y; Gao H; Wang N; Jia Z; Gao K; Liu J; Xiao C; Shang H; Wang X; Bao L; Qin C
    Signal Transduct Target Ther; 2022 Apr; 7(1):124. PubMed ID: 35436986
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunogenicity of BNT162b2 Vaccination against SARS-CoV-2 Omicron Variant and Attitudes toward a COVID-19 Booster Dose among Healthy Thai Adolescents.
    Assavavongwaikit P; Chantasrisawad N; Himananto O; Phasomsap C; Klawaja P; Cartledge S; Nadsasarn R; Jupimai T; Kawichai S; Anugulruengkitt S; Puthanakit T; On Behalf Of The Study Team
    Vaccines (Basel); 2022 Jul; 10(7):. PubMed ID: 35891264
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination.
    Sheng WH; Chang SY; Lin PH; Hsieh MJ; Chang HH; Cheng CY; Yang HC; Pan CF; Ieong SM; Chao TL; Chen JP; Cheng SH; Chang SC
    J Formos Med Assoc; 2022 Apr; 121(4):766-777. PubMed ID: 35305895
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population.
    Intapiboon P; Seepathomnarong P; Ongarj J; Surasombatpattana S; Uppanisakorn S; Mahasirimongkol S; Sawaengdee W; Phumiamorn S; Sapsutthipas S; Sangsupawanich P; Chusri S; Pinpathomrat N
    Vaccines (Basel); 2021 Nov; 9(12):. PubMed ID: 34960122
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SW-BIC-213, as a heterologous booster in healthy adults: an open-labeled, two-centered and multi-arm randomised, phase 1 trial.
    Gui YZ; Li XN; Li JX; Shen MY; Zhang MW; Cao Y; Xu HR; Li H; Cheng J; Pan L; Yi YL; Liang LY; Yu CY; Liu GY; Yu C; Hu BJ; Zhu FC; Liang F; Shen H; Jia JY; Li HW; Zhou J; Fan J
    EBioMedicine; 2023 May; 91():104586. PubMed ID: 37099843
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Booster BNT162b2 COVID-19 Vaccination Increases Neutralizing Antibody Titers Against the SARS-CoV-2 Omicron Variant in Both Young and Elderly Adults.
    Um J; Choi YY; Kim G; Kim MK; Lee KS; Sung HK; Kim BC; Lee YK; Jang HC; Bang JH; Chung KH; Oh MD; Park JS; Jeon J
    J Korean Med Sci; 2022 Mar; 37(9):e70. PubMed ID: 35257525
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sequential immunization with SARS-CoV-2 RBD vaccine induces potent and broad neutralization against variants in mice.
    Song S; Zhou B; Cheng L; Liu W; Fan Q; Ge X; Peng H; Fu YX; Ju B; Zhang Z
    Virol J; 2022 Jan; 19(1):2. PubMed ID: 34983583
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.
    Jara A; Undurraga EA; Zubizarreta JR; González C; Pizarro A; Acevedo J; Leo K; Paredes F; Bralic T; Vergara V; Mosso M; Leon F; Parot I; Leighton P; Suárez P; Rios JC; García-Escorza H; Araos R
    Lancet Glob Health; 2022 Jun; 10(6):e798-e806. PubMed ID: 35472300
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Humoral immunity and transcriptome differences of COVID-19 inactivated vacciane and protein subunit vaccine as third booster dose in human.
    Zhang Y; Yao M; Guo X; Han S; Zhang S; Zhang J; Jiang X; Wang J; Fang M; Wang S; Pang B; Liu X; Kou Z; Jiang X
    Front Immunol; 2022; 13():1027180. PubMed ID: 36341453
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants.
    Lee IJ; Sun CP; Wu PY; Lan YH; Wang IH; Liu WC; Yuan JP; Chang YW; Tseng SC; Tsung SI; Chou YC; Kumari M; Lin YS; Chen HF; Chen TY; Lin CC; Chiu CW; Hsieh CH; Chuang CY; Cheng CM; Lin HT; Chen WY; Hsu FF; Hong MH; Liao CC; Chang CS; Liang JJ; Ma HH; Chiang MT; Liao HN; Ko HY; Chen LY; Ko YA; Yu PY; Yang TJ; Chiang PC; Hsu ST; Lin YL; Lee CC; Wu HC; Tao MH
    J Biomed Sci; 2022 Jul; 29(1):49. PubMed ID: 35799178
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine.
    Chansaenroj J; Suntronwong N; Kanokudom S; Assawakosri S; Yorsaeng R; Vichaiwattana P; Klinfueng S; Wongsrisang L; Srimuan D; Thatsanatorn T; Thongmee T; Auphimai C; Nilyanimit P; Wanlapakorn N; Sudhinaraset N; Poovorawan Y
    Vaccines (Basel); 2022 Jul; 10(7):. PubMed ID: 35891235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.